Index RUT
P/E -
EPS (ttm) -1.23
Insider Own 19.01%
Shs Outstand 333.93M
Perf Week -5.14%
Market Cap 554.33M
Forward P/E -
EPS next Y -0.75
Insider Trans 0.04%
Shs Float 270.44M
Perf Month -45.93%
Income -375.36M
PEG -
EPS next Q -0.29
Inst Own 63.48%
Short Float 27.57%
Perf Quarter -70.20%
Sales 212.68M
P/S 2.61
EPS this Y 10.19%
Inst Trans 1.43%
Short Ratio 5.75
Perf Half Y -82.87%
Book/sh 2.30
P/B 0.72
EPS next Y 34.83%
ROA -40.88%
Short Interest 74.57M
Perf Year -84.51%
Cash/sh 1.08
P/C 1.54
EPS next 5Y 47.62%
ROE -51.85%
52W Range 1.65 - 12.51
Perf YTD -77.57%
Dividend Est. -
P/FCF -
EPS past 5Y 4.17%
ROI -46.22%
52W High -86.73%
Beta 0.85
Dividend TTM -
Quick Ratio 3.64
Sales past 5Y 2739.80%
Gross Margin 11.01%
52W Low 0.61%
ATR (14) 0.30
Dividend Ex-Date -
Current Ratio 4.18
EPS Y/Y TTM 32.07%
Oper. Margin -187.50%
RSI (14) 26.56
Volatility 9.85% 8.74%
Employees 838
Debt/Eq 0.07
Sales Y/Y TTM 11070.12%
Profit Margin -176.49%
Recom 1.85
Target Price 10.70
Option/Short Yes / Yes
LT Debt/Eq 0.06
EPS Q/Q 15.22%
Payout -
Rel Volume 1.42
Prev Close 1.76
Sales Surprise -40.12%
EPS Surprise -48.94%
Sales Q/Q 6798.46%
Earnings May 08 AMC
Avg Volume 12.97M
Price 1.66
SMA20 -42.20%
SMA50 -48.15%
SMA200 -76.81%
Trades
Volume 18,483,407
Change -5.68%
Date
Action
Analyst
Rating Change
Price Target Change
Today Downgrade
UBS
Buy → Neutral
$2
May-12-25 Downgrade
Truist
Buy → Hold
May-09-25 Downgrade
Citizens JMP
Mkt Outperform → Mkt Perform
Oct-24-24 Initiated
UBS
Buy
$17
Jul-29-24 Downgrade
Piper Sandler
Overweight → Neutral
$19 → $10
Nov-20-23 Initiated
Goldman
Buy
$12
Sep-18-23 Reiterated
Barclays
Overweight
$40 → $18
May-30-23 Upgrade
Wells Fargo
Equal Weight → Overweight
$11 → $17
Mar-27-23 Resumed
Wells Fargo
Equal Weight
$11
Jan-27-23 Upgrade
Piper Sandler
Neutral → Overweight
$11 → $14
Dec-09-22 Downgrade
Goldman
Buy → Neutral
$20 → $6
Oct-31-22 Initiated
Guggenheim
Neutral
Aug-18-22 Resumed
Wells Fargo
Equal Weight
$14
Jan-28-22 Upgrade
Stifel
Hold → Buy
$23 → $25
Dec-07-21 Resumed
Cowen
Outperform
Jun-10-21 Upgrade
JMP Securities
Mkt Perform → Mkt Outperform
$32
May-20-21 Downgrade
Piper Sandler
Overweight → Neutral
$35 → $18
May-19-21 Downgrade
Stifel
Buy → Hold
May-19-21 Downgrade
JMP Securities
Mkt Outperform → Mkt Perform
May-03-21 Initiated
Truist
Buy
$50
Show Previous Ratings
May-15-25 05:14AM
May-13-25 09:00AM
08:53AM
May-11-25 11:15AM
May-09-25 07:56PM
(Business Wire) -44.79%
+10.29%
11:33AM
Loading…
11:33AM
11:03AM
08:06AM
03:40AM
May-08-25 05:30PM
04:23PM
(Associated Press Finance)
04:01PM
May-07-25 05:20PM
May-06-25 08:10AM
03:15AM
04:01PM
Loading…
May-02-25 04:01PM
Apr-30-25 05:14AM
Apr-23-25 04:15PM
06:10AM
Apr-22-25 07:09AM
Apr-19-25 10:00AM
Apr-18-25 05:44PM
05:30PM
Apr-16-25 10:02AM
Apr-14-25 10:05AM
Apr-09-25 09:45AM
Apr-07-25 08:09AM
Apr-03-25 12:07PM
Mar-28-25 04:30PM
Mar-25-25 05:43PM
01:56PM
Loading…
Mar-22-25 01:56PM
11:05AM
Mar-21-25 05:15PM
Mar-17-25 03:46PM
Mar-12-25 10:15AM
Mar-04-25 07:36AM
Feb-28-25 02:37AM
Feb-27-25 05:25PM
04:29PM
(Associated Press Finance)
04:01PM
Feb-21-25 05:15PM
Feb-20-25 10:01AM
Feb-18-25 04:01PM
Feb-12-25 05:30PM
Feb-10-25 07:00AM
Jan-30-25 07:30AM
Jan-29-25 08:30AM
Jan-27-25 04:31AM
Jan-20-25 03:10PM
Jan-18-25 06:50PM
Jan-17-25 05:00PM
Jan-09-25 04:20AM
Jan-02-25 07:03PM
03:24AM
Dec-20-24 05:00PM
Dec-19-24 04:02AM
Dec-17-24 05:29AM
Dec-12-24 10:00AM
Dec-07-24 11:08AM
Nov-27-24 06:30AM
Nov-26-24 04:01PM
Nov-23-24 11:35AM
10:31AM
Nov-22-24 10:00AM
07:49AM
Nov-14-24 08:00AM
Nov-08-24 08:03AM
Nov-07-24 05:45PM
04:42PM
(Associated Press Finance)
04:01PM
Oct-31-24 04:01PM
(GlobeNewswire) -5.43%
+7.18%
Oct-24-24 06:01PM
Oct-18-24 11:01AM
Oct-16-24 07:15PM
Oct-12-24 12:28PM
Oct-10-24 10:39AM
Oct-09-24 08:03AM
Oct-04-24 08:30AM
Sep-26-24 08:15AM
Sep-16-24 06:29AM
Sep-14-24 05:32PM
Sep-06-24 09:30AM
Sep-03-24 05:00PM
Sep-02-24 06:15PM
Aug-27-24 04:36AM
Aug-16-24 05:00PM
Aug-14-24 07:15AM
Aug-09-24 12:23PM
09:27AM
Aug-08-24 05:30PM
04:24PM
(Associated Press Finance)
04:01PM
Aug-01-24 10:01AM
Jul-31-24 05:31AM
Jul-29-24 06:24PM
04:01PM
08:31AM
Jul-19-24 05:00PM
Jul-17-24 02:29PM
Jul-14-24 05:45AM
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Vogt Frederick G Interim CEO & General Counsel May 14 '25 Buy 1.69 25,000 42,250 374,646 May 16 04:05 PM Puri Raj K. Chief Regulatory Officer Mar 14 '25 Option Exercise 0.00 8,334 0 203,761 Mar 18 08:30 PM Bellemin Jean-Marc Chief Financial Officer Mar 03 '25 Option Exercise 0.00 58,590 0 87,938 Mar 05 08:33 PM BILINSKY IGOR Chief Operating Officer Mar 03 '25 Option Exercise 0.00 62,106 0 120,880 Mar 05 08:32 PM Vogt Frederick G Interim CEO & General Counsel Mar 03 '25 Option Exercise 0.00 223,943 0 445,059 Mar 05 08:32 PM Puri Raj K. Chief Regulatory Officer Mar 03 '25 Option Exercise 0.00 59,999 0 215,411 Mar 05 08:31 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Mar 03 '25 Option Exercise 0.00 62,497 0 126,383 Mar 05 08:30 PM Vogt Frederick G Interim CEO & General Counsel Jan 14 '25 Option Exercise 0.00 20,835 0 231,071 Jan 16 06:01 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Jan 14 '25 Option Exercise 0.00 2,813 0 65,464 Jan 16 06:00 PM BILINSKY IGOR Chief Operating Officer Jan 14 '25 Option Exercise 0.00 2,813 0 60,352 Jan 16 05:59 PM Puri Raj K. Chief Regulatory Officer Dec 16 '24 Option Exercise 0.00 8,334 0 159,171 Dec 18 05:15 PM Vogt Frederick G Interim CEO & General Counsel Dec 02 '24 Option Exercise 0.00 10,417 0 214,662 Dec 04 04:31 PM BILINSKY IGOR Chief Operating Officer Dec 02 '24 Option Exercise 0.00 3,516 0 59,323 Dec 04 04:30 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Dec 02 '24 Option Exercise 0.00 3,906 0 64,633 Dec 04 04:30 PM Maynard Ryan D Director Nov 12 '24 Option Exercise 7.45 50,000 372,500 57,500 Nov 14 05:00 PM Maynard Ryan D Director Nov 12 '24 Sale 10.06 50,000 503,000 7,500 Nov 14 05:00 PM Maynard Ryan D Director Nov 12 '24 Proposed Sale 10.06 50,000 503,104 Nov 12 07:11 PM Vogt Frederick G Interim CEO & General Counsel Oct 14 '24 Option Exercise 0.00 20,834 0 213,096 Oct 16 06:33 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Oct 14 '24 Option Exercise 0.00 2,813 0 62,155 Oct 16 06:32 PM BILINSKY IGOR Chief Operating Officer Oct 14 '24 Option Exercise 0.00 2,813 0 57,235 Oct 16 06:30 PM Vogt Frederick G Interim CEO & General Counsel Sep 03 '24 Option Exercise 0.00 57,292 0 212,175 Sep 05 07:56 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Sep 03 '24 Option Exercise 0.00 27,345 0 71,233 Sep 05 07:54 PM BILINSKY IGOR Chief Operating Officer Sep 03 '24 Option Exercise 0.00 26,954 0 66,313 Sep 05 07:53 PM Bellemin Jean-Marc Chief Financial Officer Sep 03 '24 Option Exercise 0.00 23,438 0 41,239 Sep 05 07:52 PM Vogt Frederick G Interim CEO & General Counsel Jul 15 '24 Option Exercise 0.00 20,835 0 168,160 Jul 17 08:01 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Jul 15 '24 Option Exercise 0.00 2,813 0 47,299 Jul 17 08:01 PM BILINSKY IGOR Chief Operating Officer Jul 15 '24 Option Exercise 0.00 2,813 0 42,571 Jul 17 08:00 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Jun 03 '24 Option Exercise 0.00 3,906 0 46,468 Jun 05 08:07 PM BILINSKY IGOR Chief Operating Officer Jun 03 '24 Option Exercise 0.00 3,516 0 41,542 Jun 05 08:05 PM Vogt Frederick G Interim CEO & General Counsel Jun 03 '24 Option Exercise 0.00 10,417 0 151,751 Jun 05 08:04 PM